GIP/GLP-1 & amylin agonists × body weight & composition

SynthesisJournal of Crohn's & colitis2025

Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis.

Ahmed B Bayoumy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Three numbers in the abstract

the abstract, start to end

loss was achieved using semaglutide (-9.6 kg, 95% confidence interval [CI]: -12.0; -7.2), liraglutide (-9.4 kg, 95% CI: -13.0; -5.8), and tirzepatide (-11.8 kg, 95% CI: -18.3; -5.4) after

← favours treatmentfavours comparator →
could be chance
Weight losssemaglutide vs baseline
−9.6−12.0 to −7.20
Weight lossliraglutide vs baseline
−9.4−13.0 to −5.80
Weight losstirzepatide vs baseline
−11.8−18.3 to −5.40
GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsBody weight & composition
1 / 3

6 papers cite it

2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 41071055